一周IPO动态，覆盖港股、美股、A股。 在全球 ADAS领域，禾赛亦与欧洲顶级车企已进入C样阶段，2026年量产计划正稳步推进。同时， 禾赛还斩获了全球最大汽车制造商之一丰田汽车车旗下合资品牌的全新定点，将于2026年量产。 此外，在机器人领域， 2025年上半年禾赛激光雷达出货量位居国内第一。禾赛JT系列激光雷达已累 计交付突破10万台，创下行业最快量产纪录。 今年第二季度，禾赛实现营收 7.1亿元（人民币，下同），同比增长超50%，净利润突破4,000万 元，远超GAAP层面盈利转正目标。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 禾赛 港股｜上市在即 据 IPO早知道消息，Hesai Group（以下简称"禾赛"）计划于9月16日正式以"2525"为股票代码在港 双重上市，成为"全球激光雷达回港上市第一股"。 禾赛在本次发行中共引入 6名基石投资者，累计认购1.48亿美元（约11.54亿港元）——其中，现有 股东高瓴认购5000万美元、WT Asset Management认购3000万美元、泰康人寿认购2800万美元、 宏达集团认购2000万美元、Grab和康曼德资本分 ...

Core Viewpoint - Genfleet Therapeutics is set to conduct an IPO from September 11 to 16, aiming to raise approximately HKD 15.82 billion, with a net amount of HKD 14.43 billion from the issuance of 77.6 million H-shares priced at HKD 20.39 each [2]. Group 1 - The company has secured cornerstone investments from several prominent institutions, totaling USD 100 million (approximately HKD 780 million), which accounts for about 49% of the total shares offered [2]. - Genfleet Therapeutics focuses on developing novel therapies for tumors, autoimmune, and inflammatory diseases, with a pipeline that includes eight candidate drugs, five of which are in clinical stages [2]. Group 2 - The core product GFH925 (Fluorouracil Tablets, marketed as "Dabert") is the first KRAS G12C inhibitor approved in China and the third globally, having received approval from the National Medical Products Administration in August 2024 for treating non-small cell lung cancer (NSCLC) [3]. - GFH925 demonstrated a 49.1% objective response rate and a 90.5% disease control rate in key clinical trials, showcasing significant clinical advantages [3]. - The product is being commercialized in collaboration with Innovent Biologics (1801.HK), and efforts are underway to advance market access [3]. Group 3 - The company is also advancing the overseas clinical development of GFH925, with a completed Phase Ib trial in the EMA regulatory region, testing its combination with cetuximab as a first-line treatment for advanced NSCLC [4]. - The Phase II portion of this trial is expected to be completed by Q4 2025, with the potential for synergistic effects in inhibiting the EGFR-RAS pathway [4]. - Another core product, GFH375, an oral KRAS G12D inhibitor, is currently undergoing Phase II clinical trials in China, and Genfleet has entered into a licensing agreement with Verastem (VSTM.US) for three candidate products, including GFH375, for development and commercialization outside Greater China [4]. Group 4 - The funds raised from the IPO will primarily be used to advance the global clinical development of core products, expand the product pipeline, enhance CMC capabilities, and supplement working capital [4].